Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment
Author:
Funder
Taipei Medical University
National Health Research Institutes
Ministry of Science and Technology, Taiwan
Publisher
Elsevier BV
Subject
Multidisciplinary
Reference43 articles.
1. Metabolic barriers to cancer immunotherapy;DePeaux;Nat Rev Immunol,2021
2. Use of tumour-responsive T cells as cancer treatment;Disis;Lancet,2009
3. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy;Nagarsheth;Nat Rev Immunol,2017
4. Mutational and antigenic landscape in tumor progression and cancer immunotherapy;Vitale;Trends Cell Biol,2019
5. T cell dysfunction in cancer immunity and immunotherapy;Xia;Front immunol,2019
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Small molecules targeting HDAC6 for cancer treatment: Current progress and novel strategies;Biomedicine & Pharmacotherapy;2024-09
2. Small molecule inhibitors targeting heat shock protein 90: An updated review;European Journal of Medicinal Chemistry;2024-09
3. Advances in dual-targeting inhibitors of HDAC6 for cancer treatment;European Journal of Medicinal Chemistry;2024-09
4. European Journal of Medicinal Chemistry Rationally Designed Febuxostat-Based Hydroxamic Acid and its pH-Responsive Nanoformulation Elicits Anti-Tumor Activity;European Journal of Medicinal Chemistry;2024-09
5. Searching for Novel HDAC6/Hsp90 Dual Inhibitors with Anti-Prostate Cancer Activity: In Silico Screening and In Vitro Evaluation;Pharmaceuticals;2024-08-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3